The one-time gene therapy is developed by a company, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S.

each year. The therapy, given in a one-hour infusion, was approved for children under age 2 and will be available within two weeks.